Showing 3611-3620 of 19355 results for "".
Data Dive: Clinical Evidence Behind CELMoDs
https://reachmd.com/programs/cme/data-dive-clinical-evidence-behind-celmods/36568/Beyond the Horizon in Multiple Myeloma: Harnessing Novel CELMoD Mechanisms for Increased Antimyeloma ActivityMolecular Magic: Decoding the Unique Mechanism of CELMoDs
https://reachmd.com/programs/cme/molecular-magic-decoding-the-unique-mechanism-of-celmods/36562/Beyond the Horizon in Multiple Myeloma: Harnessing Novel CELMoD Mechanisms for Increased Antimyeloma ActivityTargeting cardiac energetics with cardiac mitotrope in nonobstructive HCM
https://reachmd.com/programs/acc-action-center/targeting-cardiac-energetics-with-cardiac-mitotrope-in-nonobstructive-hcm/24346/ACC.24 - There is an unmet treatment need for nonobstructive hypertrophic cardiomyopathy (nHCM). Martin Maron shares the results of IMPROVE-HCM, which evaluated the efficacy and safety of the novel cardiac mitotrope ninerafaxstat in nHCM.Opportunities and Challenges in the Treatment of Pediatric-Onset Multiple Sclerosis with Highly Active Disease-Modifying Therapies
https://reachmd.com/diseases-diagnoses/ms-immune-disorders/opportunities-and-challenges-in-the-treatment-of-pediatric-onset-multiple-sclerosis-with-highly-active-disease-modifying-therapies/32080/Clinical research aims to identify safer and more effective treatments for the overlooked population of children and adolescents with multiple sclerosis.Severity Assessment: Can You Pin the Stage on the Patient?
https://reachmd.com/programs/cme/severity-assessment-can-you-pin-the-stage-on-the-patient/51481/Explore IBD from diagnosis to remission with practical cases, treatment strategies, and a treat-to-target approach for optimal patient outcomes.- Lighting the Way: Exploring the Potential of Photobiomodulation for Dry AMD Treatmenthttps://reachmd.com/programs/cme/Lighting-the-Way-Exploring-the-Potential-of-Photobiomodulation-for-Dry-AMD-Treatment-2512/33041/Learn about multiwavelength PBM for the treatment of dry AMD, including the MOA, administration, eff
An Expert’s Approach to a Difficult-to-Manage Condition: Breaking the rCDI Cycle with a Microbiome-Focused Strategy
https://reachmd.com/programs/medical-industry-feature/breaking-rcdi-cycle-microbiome-strategy/35918/Recurrent C. difficile infection (rCDI) presents a significant physical and emotional burden for both patients and caregivers. VOWST®(fecal microbiota spores, live-brpk) capsules is the only FDA-approved, orally administered microbiome therapeutic used following antibiotics to prevent rCDI. Hear froTranslating Clinical Data Into Multidisciplinary Practice for ES-SCLC
https://reachmd.com/programs/cme/translating-clinical-data-into-multidisciplinary-practice-for-es-sclc/37878/Explore recent clinical data on B7-H3 ADCs in ES-SCLC, with expert insights on biological rationale, efficacy outcomes, safety profiles, and patient selection.Advancing Care in HNSCC: Evolving Strategies Across the Disease Continuum
https://reachmd.com/programs/cme/advancing-care-in-hnscc-evolving-strategies-across-the-disease-continuum/48999/Experts explain how emerging clinical data and novel therapeutic strategies in HNSCC can expand our treatment armamentarium and improve patient outcomes.Direct from the Heart Failure Clinic: Novel Device Therapy for Patients with HFrEF
https://reachmd.com/programs/cme/direct-from-the-heart-failure-clinic-novel-device-therapy-for-patients-with-hfref/14473/Learn about baroreflex activation therapy (BAT), an implantable, FDA-approved cardiac device that’s improving exercise capacity, QoL & more.